Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
P Ponikowski, DJ Van Veldhuisen… - European heart …, 2015 - academic.oup.com
Aim The aim of this study was to evaluate the benefits and safety of long-term iv iron therapy
in iron-deficient patients with heart failure (HF). Methods and results CONFIRM-HF was a …
in iron-deficient patients with heart failure (HF). Methods and results CONFIRM-HF was a …
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
Objective To assess over 3 years of follow-up the effects of maintaining or switching to
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
M Dall'Era, D Stone, V Levesque… - Arthritis care & …, 2011 - Wiley Online Library
Objective There is a need to identify clinical characteristics and/or biomarkers that can
predict treatment outcome in lupus nephritis. To this end, we utilized data from the Aspreva …
predict treatment outcome in lupus nephritis. To this end, we utilized data from the Aspreva …
Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis
J O'Muircheartaigh, I Vavasour… - Human Brain …, 2019 - Wiley Online Library
Quantitative magnetic resonance imaging (MRI) techniques have been developed as
imaging biomarkers, aiming to improve the specificity of MRI to underlying pathology …
imaging biomarkers, aiming to improve the specificity of MRI to underlying pathology …
Rationale and design of the CONFIRM‐HF study: a double‐blind, randomized, placebo‐controlled study to assess the effects of intravenous ferric carboxymaltose on …
P Ponikowski, DJ Van Veldhuisen… - ESC heart …, 2014 - Wiley Online Library
Background Iron deficiency (ID) is a common co‐morbidity associated with chronic heart
failure (CHF), which has unfavourable clinical and prognostic consequences. In Ferinject …
failure (CHF), which has unfavourable clinical and prognostic consequences. In Ferinject …
Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
M Dall'Era, V Levesque, N Solomons… - Lupus science & …, 2015 - lupus.bmj.com
Objective To identify factors associated with clinical outcome in patients with lupus nephritis.
Methods Data from the Aspreva Lupus Management Study (ALMS) were analysed. Using …
Methods Data from the Aspreva Lupus Management Study (ALMS) were analysed. Using …
Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
EL MacMillan, JJ Schubert… - Multiple Sclerosis …, 2019 - journals.sagepub.com
Background Magnetic resonance spectroscopy quantitatively monitors biomarkers of neuron-
myelin coupling (N-acetylaspartate (NAA)), and inflammation (total creatine (tCr), total …
myelin coupling (N-acetylaspartate (NAA)), and inflammation (total creatine (tCr), total …
Advanced Myelin-related MRI Measures in Relapsing Multiple Sclerosis Patients treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks (P6. 371)
Objective: To evaluate the effect of ocrelizumab (OCR) and interferon beta-1a (IFNb-1a) on
myelin-related MRI outcomes over 2 years in relapsing multiple sclerosis (MS). Background …
myelin-related MRI outcomes over 2 years in relapsing multiple sclerosis (MS). Background …
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open …
Objective: To assess the efficacy of switching to or maintaining ocrelizumab (OCR) therapy
on MRI measures of disease activity and progression in the open-label extension (OLE) …
on MRI measures of disease activity and progression in the open-label extension (OLE) …
Confirmed Disability Progression in Different Subgroups of Patients With Relapsing Multiple Sclerosis Who Received Ocrelizumab or Interferon Beta-1a in the Phase …
Objective: To assess ocrelizumab vs interferon beta-1a (IFNβ1a) on 12-and 24-week
confirmed disability progression (CDP) in subgroups of the pooled Phase III OPERA I and …
confirmed disability progression (CDP) in subgroups of the pooled Phase III OPERA I and …